First American Trust’s Palisade Bio PALI Stock Holding History

First American Trust’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-27	Closed	-$2K	–	159
2022 Q3	$2K	Hold	27	–	–	﹤0.01%	151
2022 Q2	$8K	Buy	+27	New	+$13K	﹤0.01%	155

Other funds holding PALI

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First American Trust's PALI Position: Q4 2022 in Review

First American Trust sold out of Palisade Bio (PALI) in Q4 2022, closing a stake of 27 shares — an estimated $2K sold.

First American Trust first reported a position in PALI in Q2 2022 and held it in 2 quarters. The position peaked at $8K in Q2 2022. 11 funds tracked by Wall St. Rank hold PALI as of Q4 2022.

First American Trust reported no remaining Palisade Bio position as of Q4 2022 after selling out during the quarter.
First American Trust sold 27 Palisade Bio shares in Q4 2022, an estimated $2K.
First American Trust first reported a position in Palisade Bio in Q2 2022 and held it in 2 quarters.
First American Trust's Palisade Bio position peaked at $8K in Q2 2022.
11 funds tracked by Wall St. Rank held Palisade Bio as of Q4 2022.

Based on First American Trust's 13F filing for Q4 2022, filed 25 Jan 2023.